These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 22099607)

  • 1. Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors.
    Papakostas GI; Fan H; Tedeschini E
    Eur Neuropsychopharmacol; 2012 May; 22(5):347-55. PubMed ID: 22099607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
    J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies.
    Papakostas GI; Stahl SM; Krishen A; Seifert CA; Tucker VL; Goodale EP; Fava M
    J Clin Psychiatry; 2008 Aug; 69(8):1287-92. PubMed ID: 18605812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
    Bandelow B; Baldwin DS; Dolberg OT; Andersen HF; Stein DJ
    J Clin Psychiatry; 2006 Sep; 67(9):1428-34. PubMed ID: 17017830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions.
    Papakostas GI; Kornstein SG; Clayton AH; Soares CN; Hallett LA; Krishen A; Tucker VL
    Int Clin Psychopharmacol; 2007 Jul; 22(4):226-9. PubMed ID: 17519646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
    Lam RW; Lönn SL; Despiégel N
    Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
    Fava M; Rush AJ; Alpert JE; Balasubramani GK; Wisniewski SR; Carmin CN; Biggs MM; Zisook S; Leuchter A; Howland R; Warden D; Trivedi MH
    Am J Psychiatry; 2008 Mar; 165(3):342-51. PubMed ID: 18172020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.
    Papakostas GI; Mischoulon D; Shyu I; Alpert JE; Fava M
    Am J Psychiatry; 2010 Aug; 167(8):942-8. PubMed ID: 20595412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies.
    Feiger AD; Flament MF; Boyer P; Gillespie JA
    Int Clin Psychopharmacol; 2003 Jul; 18(4):203-10. PubMed ID: 12817154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
    Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
    Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.
    Kroenke K; Messina N; Benattia I; Graepel J; Musgnung J
    J Clin Psychiatry; 2006 Jan; 67(1):72-80. PubMed ID: 16426091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.
    Eyding D; Lelgemann M; Grouven U; Härter M; Kromp M; Kaiser T; Kerekes MF; Gerken M; Wieseler B
    BMJ; 2010 Oct; 341():c4737. PubMed ID: 20940209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study.
    Dunlop BW; Crits-Christoph P; Evans DL; Hirschowitz J; Solvason HB; Rickels K; Garlow SJ; Gallop RJ; Ninan PT
    J Clin Psychopharmacol; 2007 Dec; 27(6):614-9. PubMed ID: 18004129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials.
    Kornstein SG; Li D; Mao Y; Larsson S; Andersen HF; Papakostas GI
    CNS Spectr; 2009 Jun; 14(6):326-33. PubMed ID: 19668123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.